Language:

Risk Management for Radiation-Induced Cardiovascular Disease (RICVD): The 2022 Consensus Statement of the Taiwan Society for Therapeutic Radiology and Oncology (TASTRO) and Taiwan Society of Cardiology (TSOC)

Acta Cardiologica Sinica, 2022-01, Vol.38 (1), p.001-012

ISSN: 1011-6842 ;DOI: 10.6515/ACS.202201_38(1).20211122A ;PMID: 35068877

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Risk Management for Radiation-Induced Cardiovascular Disease (RICVD): The 2022 Consensus Statement of the Taiwan Society for Therapeutic Radiology and Oncology (TASTRO) and Taiwan Society of Cardiology (TSOC)
Author: Lu, Long-Sheng ; Wu, Yen-Wen ; Chang, Joseph Tung-Chieh ; Chang, Wei-Ting ; Chao, Ting-Hsing ; Chen, Helen Hai-Wen ; Chen, Yu-Jen ; Cheng, Kai-Hung ; Hsu, Wen-Lin ; Hung, Chung-Lieh ; Kuo, Sung-Hsin ; Liang, Ji-An ; Lin, Hung-Ju ; Liu, Ping-Yen ; Liu, Wen-Shan ; Liu, Yen-Wen ; Shueng, Pei-Wei ; Wang, Chao-Yung ; Hou, Charles Jia-Yin ; Chiou, Jeng-Fong
Subjects: Cancer survivorship ; Cardio-oncology ; Cardiosparing radiotherapy ; Consensus ; MEDLINE ; Radiation-induced cardiovascular diseases ; Review ; SCIE ; Scopus
Is Part Of: Acta Cardiologica Sinica, 2022-01, Vol.38 (1), p.001-012
Description: Advances in cancer management have significantly improved survival in patients with cancers. Cardiovascular complications of cancer treatment are becoming significant competing causes of death in these patients. Radiotherapy is an indispensable component of cancer treatment, and irradiation of the heart and vasculature during cancer radiotherapy is now recognized as a new risk factor for cardiovascular diseases. It is important to involve multidisciplinary expertise and provide practical recommendations to promote awareness, recognize risks, and provide adequate interventions without jeopardizing cancer control. In this consensus paper, experts from the Taiwan Society for Therapeutic Radiology and Oncology and Taiwan Society of Cardiology provide a focused update on the clinical practice for risk stratification and management of radiation-induced cardiovascular disease (RICVD). We believe that implementing RICVD care under a collaborative cardio-oncology program will significantly improve cancer treatment outcomes and will facilitate high quality clinical investigations.
Publisher: 台灣: 中華民國心臟學會
Language: English;Chinese
Identifier: ISSN: 1011-6842
DOI: 10.6515/ACS.202201_38(1).20211122A
PMID: 35068877
Source: PubMed Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Risk Management for Radiation-Induced Cardiovascular Disease (RICVD): The 2022 Consensus Statement of the Taiwan Society for Therapeutic Radiology and Oncology (TASTRO) and Taiwan Society of Cardiology (TSOC)

ISSN: 1011-6842 ;DOI: 10.6515/ACS.202201_38(1).20211122A ;PMID: 35068877

Searching Remote Databases, Please Wait